Pazopanib (Votrient) is registered for the treatment of patients with advanced renal cell
carcinoma and patients with soft tissue sarcoma who have received prior chemotherapy. It is
administered at a fixed oral dose of 800 mg once daily (OD) regardless of size, age and
clinical condition. It is absorbed from the gastrointestinal tract with an oral
bioavailability of ~21%. Pazopanib is practically insoluble and highly permeable. When
ingested with high fat food the pazopanib exposure (area under the concentration time curve
(AUC)) is doubled. Common adverse effects are diarrhea and nausea. This might be caused by
the non-absorbed proportion of pazopanib. A reduced dose taken with food could be a possible
approach to reduce these side effects. Therefore the investigators initially want to
determine the equivalent reduced dose of pazopanib when taken with a continental breakfast.
Thereafter the investigators want to investigate whether the intake with food reduces the
frequently reported side effects nausea and diarrhea.